MD Pharma
ActiveActs, filings and financial milestones
Deadline for the 2026 accounts:
2026
30-07
full format · 1 day before the deadline
29-04
Gazette deed
2 directors appointed, 2 directors resigning, 3 reappointedPermanent representatives: DEBEL Mario and IMSCHOOT Anja · Reappointments: MD CONSULT (director) and AQUITANIA (director) · Resignations: MD CONSULT (director) and AQUITANIA (director)14 points ▸
Gazette deed
2 directors appointed, 2 directors resigning, 3 reappointed
Permanent representatives: DEBEL Mario and IMSCHOOT Anja · Reappointments: MD CONSULT (director) and AQUITANIA (director) · Resignations: MD CONSULT (director) and AQUITANIA (director)14 points ▸
- General meeting, 30-03-2026
- Amendment of the articles, mentioned 2 times in the deed
- Capital, €1,087,000
- Permanent representative, DEBEL Mario
- Permanent representative, IMSCHOOT Anja
- Director reappointment, MD CONSULT (director)
- Director reappointment, AQUITANIA (director)
- Director reappointment, MD CONSULT (managing director)
- Director resignation, MD CONSULT (director)
- Director resignation, AQUITANIA (director)
- Director appointment, MD CONSULT (director)
- Director appointment, AQUITANIA (director)
- The act holds 2 more points.
2025
30-07
abbreviated format · 1 day before the deadline
2024
31-12
Financial
Highest result from 2018 to 2025net €307,906 ▲0.9%
The net result of €307,906 is the highest of those years.
31-12
Financial
Liquidity more than quadruplescurrent ratio 5.34
The current ratio rises from 1.09 to 5.34.
25-07
abbreviated format · 6 days before the deadline
2023
31-12
Financial
Liquidity more than 5 timescurrent ratio 1.09
The current ratio rises from 0.19 to 1.09. Short-term debt falls from €1.1m to €196,126.
31-12
Financial
Equity above €1mequity €1.2m ▲33.1%
After 2 profitable years in a row, equity reaches €1.2m.
31-08
abbreviated format · 31 days late
2022
31-12
Financial
Back to profitnet €236,021
The net result is €236,021, after 3 loss-making years.
20-07
abbreviated format · 11 days before the deadline
15-02
Gazette deed
Registered office moved from Merelbeke to Sint-Denijs-WestremNew seat: Kortrijksesteenweg 1091 bus B, 9051 Sint-Denijs-Westrem · Previous seat: Lembergsesteenweg 29, 9820 Merelbeke2 points ▸
Gazette deed
Registered office moved from Merelbeke to Sint-Denijs-Westrem
New seat: Kortrijksesteenweg 1091 bus B, 9051 Sint-Denijs-Westrem · Previous seat: Lembergsesteenweg 29, 9820 Merelbeke2 points ▸
- Board meeting, 25-01-2022
- Registered-office move, Kortrijksesteenweg 1091 bus B, 9051 Sint-Denijs-Westrem
Show earlier events
2021
16-12
Gazette deed
Resignation: AUBISQUE BV (director)Permanent representative: Freya Lorcin3 points ▸
Gazette deed
Resignation: AUBISQUE BV (director)
Permanent representative: Freya Lorcin3 points ▸
- General meeting, 28-10-2021
- Director resignation, AUBISQUE BV (director)
- Permanent representative, Freya Lorcin
04-06
abbreviated format · 57 days before the deadline
2020
31-12
Financial
Liquidity doublescurrent ratio 30.83
The current ratio rises from 15.27 to 30.83. Short-term debt falls from €238,247 to €144,243.
25-08
abbreviated format · 25 days late
2019
31-12
Financial
Weakest financial yearnet -€129,364
The net result drops to -€129,364, the lowest from 2018 to 2025. It recovers the following year.
30-08
abbreviated format · 30 days late
2018
28-08
abbreviated format · 28 days late
2016
20-12
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank